RE:RE:RE:With results like these I wonder why why 99942Apophis ... Great post.
I would add that TLT already had a molecule from Virginia Tech when Dr. McFarland approached TLT. TLT could have turned her down or simply not listen to her, for whatever reasons. They rather took the time to listen, even if her molecule had not been tested on any animal model. Not even in vitro and in vivo.
We owe TLT management this opportunity to be in a stock that is knocking on the door of a FDA Breakthrough Therapy designation.
In history, only 3 Canadian biotechs have received a full FDA approval in oncology.
Some takes things for granted, despite the multi-disciplinary aspects and expertises required to make sure the molecule attributes didn't lose any benefits throughout the process. Heavy lifting for those that can understand what it took to get there.
It's only been 4 months since the Jan. 3rd article that outlined the new commercialization steps and it's never enough for some, despite the fact that we all know dealing with regulatory agencies is complex and slow.
TLT was not open for discussions up until that p#25 @450-days because, since before Ph. 1B, they clearly announced that they would go all alone until Ph. 2 because they believed they had something unique. Also because it would have given nothing to look for a jv before that because of lack of data as it would have hampered its ability to deliver maximum valuation when the right time would come, equipped with real convincing data that is about to have a much greater value now than what Ph. 1b could have had.
And so far, despite all the many challenges, many first, at every steps, they delivered.
________________
99942Apophis - (5/16/2023 9:47:28 PM)
RE:RE:With results like these I wonder why why
Hi Mikee3003
1. They are on the correct exchange, soon they will advance to the senior TSX following that perhaps listings in multiple foreign exchanges .
2. Postal Code is where Dr. Sherri McFarland received respect for her work and shared her vision with this company Theralase. She didn't get that respect in the US.
3. Management has brought this treatment to a point of a theory to potential SOC runner-up.